Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia

Abstract Objective Changes in immune system have been reported in schizophrenia. This study aimed to evaluate the involvement of IL-33, a member of the IL-1 cytokine family, in schizophrenia and its association with cognitive performance in these patients. Methods Forty patients with chronic schizop...

Full description

Saved in:
Bibliographic Details
Published in:Comprehensive psychiatry 2017-04, Vol.74, p.96-101
Main Authors: de Campos-Carli, Salvina Maria, Miranda, Aline Silva, Dias, Ingrid Caroline Silva, de Oliveira, Amanda, Cruz, Breno Fiuza, Vieira, Érica Leandro Marciano, Rocha, Natalia Pessoa, Barbosa, Izabela Guimarães, Salgado, João Vinícius, Teixeira, Antônio Lúcio
Format: Article
Language:English
Subjects:
Adult
Age
Alzheimer's disease
Behavior disorders
Biomarkers - blood
Cognition & reasoning
Cognition - physiology
Cognition Disorders - blood
Cognition Disorders - diagnosis
Cognition Disorders - psychology
Cognitive ability
Cytokines
Data collection
Drug dosages
Enzyme-Linked Immunosorbent Assay - methods
Female
Humans
Interleukin-1 Receptor-Like 1 Protein - blood
Interleukin-33 - blood
Male
Memory
Middle Aged
Pathogenesis
Patients
Psychiatry
Psychotropic drugs
Schizophrenia
Schizophrenia - blood
Schizophrenia - diagnosis
Schizophrenic Psychology
Studies
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective Changes in immune system have been reported in schizophrenia. This study aimed to evaluate the involvement of IL-33, a member of the IL-1 cytokine family, in schizophrenia and its association with cognitive performance in these patients. Methods Forty patients with chronic schizophrenia and 40 healthy subjects participated in the study. Serum levels of IL-33 and sST2 (soluble form of the IL-33 receptor) were measured using enzyme-linked immunosorbent assay (ELISA). Patients were evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) and the Schizophrenia Cognition Rating Scale (SCoRS). Results Patients with schizophrenia and controls presented similar serum levels of IL-33 and sST2. Levels of both markers were positively correlated with cognitive performance in patients with schizophrenia. Conclusion We found a significant correlation between IL-33 and sST2 levels and cognition in schizophrenia. Our results might help in the understanding of how immune markers are associated with cognitive impairment in schizophrenia. It remains to be determined whether the association between IL-33/sST2 and cognition is restricted to patients with schizophrenia.
ISSN:0010-440X
1532-8384
DOI:10.1016/j.comppsych.2017.01.008